Skip to main content
[Preprint]. 2020 Jul 27:2020.05.23.112235. Originally published 2020 May 23. [Version 2] doi: 10.1101/2020.05.23.112235

Figure 3:

Figure 3:

Initial screening of Mpro inhibition by 29 FDA/EMA-approved medicines and rupintrivir. 1 mM (0.14 mM for Itraconazole due to its low solubility in DMSO) was used for each inhibitor to perform the inhibition assay. Fluorescence intensity was normalized with respect to the control that had no small molecule provided. Triplicate experiments were performed for each compound, and the value was presented as mean ± standard error (SE).